Advertisement
INSM or JNJ or VRTX
Which Stock Would AI Choose? Insmed (INSM) vs. Johnson & Johnson (JNJ) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- INSM has delivered explosive growth with 1-year returns over 86%, fueled by strong revenue from BRINSUPRI and ARIKAYCE, projecting at least $1B in BRINSUPRI sales for 2026.
- JNJ offers stability as a dividend aristocrat with a 2.16% yield, YTD gains around 17%, bolstered by FDA approvals in oncology and pipeline advancements amid talc litigation.
- VRTX maintains steady performance with a P/E of about 30, driven by cystic fibrosis dominance and positive JOURNAVX pain data, alongside diversified revenue growth to $12B in 2025.
- INSM exhibits highest volatility (beta 1.17), contrasting JNJ and VRTX (betas ~0.3), appealing to growth traders versus defensive investors.
- Analyst price targets suggest upside for all, with INSM at ~$213 average, JNJ at $253, and VRTX at $536.
- Market caps differ sharply: JNJ ~$579B, VRTX ~$116B, INSM ~$30B, reflecting scale versus biotech agility.
Introduction
This stock comparison examines INSM, JNJ, and VRTX, three healthcare leaders spanning biotech innovation and established pharmaceuticals. INSM targets rare pulmonary diseases, JNJ delivers diversified medtech and drugs, and VRTX excels in cystic fibrosis therapies. Traders seeking high-momentum plays may eye INSM's surge, while long-term investors favor JNJ's stability or VRTX's pipeline. In the current market, with biotech volatility and pharma resilience, this analysis highlights relative performance, growth drivers, and risks for informed stock comparison decisions.
INSM Overview and Recent Performance
Insmed Incorporated (INSM) focuses on therapies for serious rare diseases, particularly pulmonary conditions like nontuberculous mycobacterial lung disease. Its approved products include ARIKAYCE and BRINSUPRI (brensocatib), with full-year 2025 revenues reaching $606M, up significantly year-over-year, driven by BRINSUPRI's $173M and ARIKAYCE's 19% growth to $434M. In recent market activity, INSM shares traded around $140, reflecting YTD gains near 20% despite short-term pullbacks, with 1-year returns exceeding 86%. Sentiment has been boosted by analyst upgrades, including BofA's $211 target, European approval for BRINSUPRI, and 2026 guidance of at least $1B in BRINSUPRI sales plus $450-470M from ARIKAYCE. Pipeline progress, like the INS1148 acquisition, counters a CRSsNP setback, fueling growth optimism amid high beta volatility.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) is a global healthcare giant with pharmaceuticals, medtech, and consumer health segments, known for diversified revenue and reliable dividends. Recent weeks saw shares near $240, with YTD returns around 17% and 1-year gains over 49%, outperforming broader markets. Key drivers include FDA approvals for TECVAYLI plus DARZALEX in multiple myeloma, enhancing oncology positioning, and BofA raising its target to $253 on pipeline strength. Q4 2025 results showed robust growth, though talc-related lawsuits persist, with recent verdicts like $250K in Pennsylvania and ongoing defenses. Low beta (~0.33) underscores defensive appeal, with a forward P/E near 21 and 2.16% yield supporting steady performance in volatile conditions.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals (VRTX) specializes in transformative therapies for cystic fibrosis (CF), sickle cell disease, and emerging areas like pain and kidney disease. Shares hovered around $457, with modest YTD gains and 1-year returns near 6%, backed by 2025 total revenues of $12B, up 9%. Recent momentum stems from positive JOURNAVX data showing effective non-opioid pain management post-procedures, investor conference preparations, and 2026 guidance of $12.95-13.1B revenue. CF franchise strength, CASGEVY launches, and pipeline catalysts like povetacicept sustain sentiment, with a trailing P/E of ~30 and low beta (~0.31) signaling balanced risk-reward.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases over 25 curated AI trading bots optimized for current market conditions, drawn from Tickeron’s extensive library of hundreds of AI bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like swing trading, trend following, hedging, and volatility plays, with timeframes from 5-minute to 60-minute intervals. Standouts feature annualized returns ranging from +14% to over +218%, win rates of 52-95%, and profit factors up to 25+, such as bots targeting semiconductors (SOXL at +113%), aerospace/defense, and mining with multi-ticker portfolios up to 25 assets. Only the highest-performing, market-suited bots earn trending status based on AI analysis of volatility, momentum, and sector rotations. Explore these for potential edges in dynamic environments.
Head-to-Head Comparison
INSM, JNJ, and VRTX contrast sharply in business models: INSM's rare-disease biotech focus drives hyper-growth but elevates risks from clinical setbacks, unlike JNJ's broad pharma-medtech stability and VRTX's CF-centric expansion into pain/kidney. Recent momentum favors INSM (86% 1-yr return) over JNJ (49%) and VRTX (6%), yet INSM's beta 1.17 signals volatility versus peers' ~0.3. Growth drivers include INSM/BRINSUPRI ramp-up, JNJ/oncology approvals, and VRTX/JOURNAVX. Risks: INSM execution in commercialization, JNJ talc litigation, VRTX CF revenue concentration. Valuations reflect: JNJ cheapest P/E ~22 with dividends, VRTX ~30, INSM unprofitable (high P/S). Sector exposure tilts INSM/pulmonary toward biotech sensitivity, while others offer broader resilience; sentiment leans growth for INSM, defense for rest.
Tickeron AI Verdict
Tickeron’s AI currently favors INSM for traders eyeing momentum, given its superior trend consistency, revenue catalysts like $1B+ BRINSUPRI guidance, and relative outperformance amid biotech recovery. VRTX suits balanced growth with pipeline stability, while JNJ appeals probabilistically for risk-averse positioning. Observable factors like INSM's 86% 1-year gains tip the scale, though volatility warrants caution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 1 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s), and VRTX’s FA Score reflects 1 green FA rating(s).
- INSM’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 3 green, 2 red.
- VRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 3 bullish TA indicator(s), and VRTX’s TA Score reflects 3 bullish TA indicator(s).
- INSM’s TA Score: 5 bullish, 5 bearish.
- JNJ’s TA Score: 3 bullish, 4 bearish.
- VRTX’s TA Score: 3 bullish, 6 bearish.
Price Growth
INSM (@Biotechnology) experienced а -1.72% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -0.71% , and VRTX (@Biotechnology) price fluctuated +1.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.26%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +6.73%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +6.57%.
Reported Earning Dates
INSM is expected to report earnings on Apr 30, 2026.
JNJ is expected to report earnings on Apr 14, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Biotechnology (+2.26% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INSM | JNJ | VRTX | |
| Capitalization | 34.5B | 581B | 114B |
| EBITDA | -1.18B | 41.1B | 4.87B |
| Gain YTD | -8.274 | 17.223 | -1.451 |
| P/E Ratio | N/A | 21.88 | 29.16 |
| Revenue | 606M | 94.2B | 12B |
| Total Cash | 1.43B | 20.1B | 6.61B |
| Total Debt | 587M | 47.9B | 2.03B |
INSM | JNJ | VRTX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 60 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 23 Undervalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 32 | 8 | 33 | |
SMR RATING 1..100 | 100 | 27 | 39 | |
PRICE GROWTH RATING 1..100 | 41 | 42 | 59 | |
P/E GROWTH RATING 1..100 | 100 | 77 | 49 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (23) in the Pharmaceuticals Major industry is somewhat better than the same rating for INSM (79) in the Biotechnology industry, and is somewhat better than the same rating for VRTX (81) in the Biotechnology industry. This means that JNJ's stock grew somewhat faster than INSM’s and somewhat faster than VRTX’s over the last 12 months.
JNJ's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is in the same range as INSM (32) in the Biotechnology industry, and is in the same range as VRTX (33) in the Biotechnology industry. This means that JNJ's stock grew similarly to INSM’s and similarly to VRTX’s over the last 12 months.
JNJ's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as VRTX (39) in the Biotechnology industry, and is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that JNJ's stock grew similarly to VRTX’s and significantly faster than INSM’s over the last 12 months.
INSM's Price Growth Rating (41) in the Biotechnology industry is in the same range as JNJ (42) in the Pharmaceuticals Major industry, and is in the same range as VRTX (59) in the Biotechnology industry. This means that INSM's stock grew similarly to JNJ’s and similarly to VRTX’s over the last 12 months.
VRTX's P/E Growth Rating (49) in the Biotechnology industry is in the same range as JNJ (77) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INSM (100) in the Biotechnology industry. This means that VRTX's stock grew similarly to JNJ’s and somewhat faster than INSM’s over the last 12 months.
| INSM | JNJ | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 51% | 1 day ago 70% |
| Momentum ODDS (%) | 1 day ago 68% | 1 day ago 40% | 1 day ago 47% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 50% | 1 day ago 50% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 40% | 1 day ago 42% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 42% | 1 day ago 37% |
| Advances ODDS (%) | 9 days ago 71% | 1 day ago 44% | 1 day ago 62% |
| Declines ODDS (%) | 1 day ago 73% | 3 days ago 41% | 3 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 68% | N/A | 3 days ago 74% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 33% | 1 day ago 28% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NPFD | 19.18 | 0.39 | +2.08% |
| Nuveen Variable Rate Preferred & Income Fund | |||
| SEPT | 35.45 | 0.18 | +0.51% |
| AllianzIM US Equity Buffer10 Sep ETF | |||
| BSCR | 19.66 | N/A | N/A |
| Invesco BulletShares 2027 Corp Bd ETF | |||
| FTIF | 27.59 | N/A | N/A |
| First Trust Bloomberg Infl Snstv Eq ETF | |||
| PMFB | 26.73 | N/A | N/A |
| PGIM S&P 500 Max Buffer ETF - February | |||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.